Baxter Secures Critical FDA Approval for Clinolipid’s Expanded Use
Baxter International has received FDA approval to expand the use of Clinolipid, a lipid emulsion, to include pediatric patients,...
Jon Napitupulu
Can-Fite BioPharma Proceeds with Phase 3 Liver Cancer Trial
Can-Fite BioPharma has secured approval from the FDA and EMA for a pivotal Phase 3 clinical trial for the...
Merck Terminates Investigational Melanoma Treatment Arm
Merck has terminated a clinical trial arm combining vibostolimab and pembrolizumab for treating resected high-risk melanoma. The decision was...
AC Immune and Takeda: A Remarkable Agreement for Alzheimer’s Therapy
Takeda Pharmaceutical Company and AC Immune have entered into an exclusive global option and licensing agreement for AC Immune’s...
Flatiron Health, Cancer Centers Align on Data Capture
Flatiron Health, a healthcare technology company, has joined forces with the Association of Cancer Care Centers (ACCC) to improve...
Revance Brings Game-Changing Daxxify® to Treat Cervical Dystonia in the US
Revance Therapeutics, Inc. has launched DAXXIFY (DaxibotulinumtoxinA-lanm), a novel treatment for cervical dystonia, a painful condition. This marks Revance’s...
Reflow Medical Completes Enrollment in the DEEPER-Reveal Clinical Trial
Reflow Spur™ Stent Clinical Trial Concludes Enrollment Reflow Medical, Inc. has successfully completed enrollment in the DEEPER REVEAL clinical...
Kite and Arcellx Advance Multiple Myeloma Program with Anti-BCMA CAR-T Momentum
Arcellx and Kite have partnered on the development of anitocabtagene autoleucel (anito-cel), a BCMA CAR T cell therapy for...
Merck’s KEYNOTE-B21 Trial: Failed To Meet Primary Endpoint For Endrometrial Cancer
Merck’s Phase 3 KEYNOTE-B21 trial has shown that its anti-PD-1 therapy, KEYTRUDA, in combination with chemotherapy, did not improve...
SPT-300: A Promising Oral Neurosteroid for Mood and Anxiety Disorders
Clinical trials have demonstrated the significant potential of SPT-300, an oral prodrug of the neurosteroid allopregnanolone. The Glyph™ platform...